DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for those affected by Epidermolysis bullosa (EB), today launches a call for Basic Science ...

BOSTON--(BUSINESS WIRE)--BPGbio Inc (BPG), an AI-powered biopharma with a mission to reimagine biology for humanity, announced today that the company has reached a partnership agreement with ...

BOSTON, Oct. 27, 2017 /PRNewswire/ -- BERG, a biopharmaceutical company that merges biology with technology, today announced that the Company was honored with a Partners in Progress Award from the ...

The financing supports Eliksa’s clinical development of ELK-003, a biological eye drop for ocular complications in Epidermolysis bullosa (EB) patients. The ongoing pilot study in cooperation with ...

Initial programs will focus on developing innovative topical treatments and drug therapies for wound healing and itch relief, plus prophylactic therapies for people with Epidermolysis Bullosa.

EB charity Debra Ireland has launched an appeal this Christmas to raise funds for extra supports, including home nursing hours, for 300 families in Ireland with children suffering from this genetic ...

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. Fibrocell Science, Inc., an autologous cell therapy company with its primary focus on developing innovative ...

National charity DEBRA, which offers specialist care to those suffering from Epidermolysis Bullosa (EB), has unveiled a hard-hitting Facebook app with Publicis London to help raise awareness of the ...

An Irish engineer who climbed Mount Kilimanjaro in honor of his late brother now plans to row the Irish Sea to raise awareness about the rare disease that he died of, epidermolysis bullosa (EB).

Additional investors include global investment firm Viking Global Investors, charity foundation CureEB, the Epidermolysis Bullosa Medical Research Foundation (EBMRF), and Stanford University. The ...